KALOS THERAPEUTICS
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of cancer. Kalos is aggressively targeting diseases caused by an abnormally high growth rate of cells (hyperproliferation). Kalos is pioneering an approach to cancer treatment by developing peptides made primarily in the heart as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small-molecule compounds.
KALOS THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.kalostherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
+1 858 552 6890
Email Addresses:
[email protected]
Total Funding:
958.03 K USD
Technology used in webpage:
SPF Amazon GoDaddy DNS YouTube GStatic Google Static Content DoubleClick.Net AWS Global Accelerator Zoho Mail
Similar Organizations
Akebia Therapeutics
Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Conforma Therapeutics
Conforma Therapeutics Corporation designs and develops drugs for the treatment of cancer.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Leonardo Biosystems
Leonardo Biosystems is a provider of a proprietary multistage drug delivery platform for the treatment of cancer.
Lysosomal Therapeutics
Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
Oncolyze
Oncolyze is developing a disruptive technology for the treatment of cancer.
Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
TNK Therapeutics
TNK Therapeutics develops chimeric antigen receptor immunotherapy programs.
Current Employees Featured
Founder
Official Site Inspections
http://www.kalostherapeutics.com Semrush global rank: 5.88 M Semrush visits lastest month: 1.41 K
- Host name: 209.17.116.160
- IP address: 209.17.116.160
- Location: Jacksonville United States
- Latitude: 30.1426
- Longitude: -81.5727
- Metro Code: 561
- Timezone: America/New_York
- Postal: 32258
More informations about "Kalos Therapeutics"
Kalos Therapeutics - Crunchbase Company Profile & Funding
Kalos Therapeutics is an emerging biomedical company with the exclusive patent to develop the ANP (atrial natriuretic peptide) family of peptides as a new mechanism for the treatment of …See details»
Kalos Therapeutics - PitchBook
Kalos Therapeutics General Information Description. Developer of atrial natriuretic peptides designed to help in the treatment of cancer in patients. The company's peptides develop a …See details»
Kalos Therapeutics - LinkedIn
Kalos Therapeutics | 374 followers on LinkedIn. Kalos is developing drugs based on a platform of short amino acids creating therapeutic approaches for orphan, unmet and | Kalos Therapeutics is a ...See details»
KALOS THERAPEUTICS INC Company Profile - Dun & Bradstreet
Kalos therapeutics inc. d&b business directory home / business directory / professional, scientific, and technical services / scientific research and development services / united states / arizona / …See details»
Meet Kalos Therapeutics: Phoenix-based biomedical …
Dec 4, 2019 George Colberg: Kalos Therapeutics, Inc. is pioneering the first nontoxic therapy to treat primary tumors and metastasis. Kalos can be a lead, combination and safe long-term therapy for cancer. This approach will allow …See details»
KALOS Therapeutics, Inc. - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... KALOS Therapeutics, Inc. …See details»
Kalos Therapeutics - Contacts, Employees, Board Members
Kalos Therapeutics has 4 current employee profiles, including President and CMO of Kalos Therapeutics James Merritt. James Merritt President and CMO of Kalos Therapeutics George …See details»
Kalos Therapeutics Company Profile - Office Locations ... - Craft
Kalos Therapeutics is a company that provides nontoxic endogenous peptide therapy to treat cancers and related comorbidities. It develops KTH-222, a drug candidate designed to …See details»
Kalos Therapeutics - VentureRadar
Kalos is developing a groundbreaking approach to treating cancers and related co-morbidities. The Company’s revolutionary technology is based upon... ... Find out ...See details»
Kalos Therapeutics - Updates, News, Events, Signals & Triggers
Dec 27, 2019 Organization. Kalos Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Newswire — …See details»
KALOS Therapeutics | Phoenix AZ - Facebook
KALOS Therapeutics, Phoenix, Arizona. 1,476 likes · 9 were here. Devoted to treating the unmet needs of people living with incurable diseases through discovery and development of nontoxic endogenous...See details»
Oncology Pharma Licensor and Co-Development Partner, Kalos …
Apr 21, 2020 PHOENIX, AZ / ACCESSWIRE / April 21, 2020 / Kalos Therapeutics announced its latest progress in its efforts to discover and develop a novel multi-drug cocktail of …See details»
Oncology Pharma Licensor and Co-Development Partner, Kalos …
SAN FRANCISCO, April 22, 2020 (Newswire.com) - Kalos Therapeutics announced its latest progress in its efforts to discover and develop a novel multi-drug cocktail of investigational …See details»
Oncology Pharma Announces Extension of Letter of Intent with …
Aug 27, 2020 --via NEWMEDIAWIRE-- Oncology Pharma, Inc. is pleased to announce that it has extended its Letter of Intent with Kalos Therapeutics.. George Malasek was brought into …See details»
Oncology Pharma and Kalos Therapeutics Expand Licensing
Apr 6, 2020 about kalos therapeutics, inc. Kalos is pursuing a multi-phase strategy to reorient today's therapeutic approach to cancer patients while driving changes to transform therapeutic …See details»
Kalos therapeutics announces important progress in therapeutic …
Kalos therapeutics is developing a novel, small peptide with activity against human pancreatic cancer Phoenix, May 30, 2020 (Issuewire.com) – Kalos Therapeutics (KTPX), a preclinical …See details»
Kalos Therapeutics, Inc., Oncology Pharmaceuticals and ... - Nasdaq
Sep 30, 2019 Kalos Therapeutics, Inc. CEO, George Colberg, announced that the collaboration with the Oncology Pharma has provided new opportunities for Kalos to advance its drug …See details»
Oncology Pharma Signed a Letter of Intent with Kalos
Aug 19, 2019 Kalos Therapeutics is developing a platform of drugs containing multiple array of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with …See details»
Oncology Pharma Announces Extension of Letter of Intent
San Francisco, CA, Aug. 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Oncology Pharma, Inc. (OTCPK: ONPH) is pleased to announce that it has extended its Letter of Intent …See details»
Kalos Therapeutics, Inc., Oncology Pharmaceuticals and ... - AZBio
Oct 5, 2019 Mr. George Colberg (CEO, Kalos Therapeutics) stated: “synergistic therapies based on pairing of two or more drugs such as KTH-222 and doxorubicin have the potential of being …See details»